但是我们可以发现其实州内的这些波动是比较大的主要就是最近一段时间整个市场其实消息面比较分就是比较难辨别因为每天市场上有各种各样的这种小道消息出来但是呢又没有被证伪但从现在来看很多人都看那个消息呢真真假假其实就真一半假一半吧所以说整个行情呢就会出现这种 消息来的时候可能就波动一下然后发现这个消息是假消息又回到基本面的这样一个初期的一个状态所以说最近一段时间无论是邮局也好 三百货也好可能在操作上其实都是比较难操作的但我个人觉得从现在来看无论是三百货还是邮局可能都是一个区间震荡的这样一种走势但目前来说可能还没有出现一个非常明朗的这样的一个趋势性行情出来首先我们看一下美标市场 美洲现在是处于一个弱见时和强欲期的一种撕裂中首先看一下巴西现在整个主产中马托柏罗索已经收割接近尾声总的总收割率已经接近七成所以说巴西的丰产的压力目前已经开始陆续在释放巴西大陆整个出入中转也在增加 由于港口中堵,整个巴西的升级水,上周前半段是不断的在大幅的上涨到后半段的时间,整个巴西升级水就稳定到一个这样一个区间内 那么这也就使得整个目前整个对于美东来讲它的这个供给端还是有一定的压力那么从这个它这个中美包括这个美国与其他国家的这样一个关税情况来看 ...

打造了采讯数字员工产品同时也利用这个agent的能力实现对企业内部信息系统原有能力的一个整合来帮助企业提升营销率公司的数字员工目前是已经在不动产智能顾问办公助手等等这些场景实现了落地我们认为公司这项业务它未来会主要受到新创以及AI的一个驱动 系统办公平台它作为办公管理系统非常重要的组成部分信创渗透程度也是很深的信创邮箱系统作为企业信息化管理的中央一环借助信创知识也是逐渐的释放一个国产化替代的这样一个需求公司信创邮箱有望凭借它比较强大的客户基础以及全站的信创适配能力 感谢大家本网参加平安证券TMT团队的电话会议今天分享的是采讯股份的首次覆盖报告题目是新创邮箱领先企业AI权占布局拓展价值边界采讯股份它是我们国产邮箱领域的一个领先企业最早是做手机邮箱业务起家的目前是由协同办公智慧渠道云大数据这三大产品线 并且在AI方面也是实现了从算力到算法的一个全站的过去那公司和中微移动是有着非常紧密的一个合作关系的公司被靠中移积极的拓展它的下游与很多的行业的同步客户都形成了一个密切的合作那也确立了行业内的一个优势的竞争地位 业绩方面呢公司在2024年带三季度业绩表现是非常良好的收入是实现了4.29亿元实现了19.26%的这样一个 ...

Summary of Conference Call Company and Industry Overview - The conference call primarily discusses a pharmaceutical company involved in the development of innovative drugs and generic medications, focusing on mental health treatments and gastrointestinal diseases [1][2][3]. Key Points and Arguments 1. **Pipeline Development**: The company is advancing its pipeline, particularly with the drug 11502 for schizophrenia, which also targets depression and bipolar disorder. Phase II enrollment has been completed, and data analysis is pending [1]. 2. **Sales Growth Expectations**: The company anticipates sales growth for the drug Didaxine, aiming for over 100 million yuan in revenue this year, supported by an increase in hospital enrollments from 600 to an expected 700 additional hospitals [3][4]. 3. **Clinical Trials**: The company has initiated formal clinical enrollment for its products, with expectations to complete Phase I trials by the end of the year [4]. 4. **Government Policy Impact**: The company is optimistic about the government's drug procurement policies, believing that a balanced approach to pricing, quality, and supply will benefit their operations [6]. 5. **Innovation Focus**: The company emphasizes its commitment to innovation, with a budget of approximately 10% of revenue allocated for R&D, focusing on mental health and cardiovascular diseases [8]. 6. **Cost Management**: The company has successfully reduced sales expenses while improving operational efficiency, which is expected to continue into 2025 [9][10]. 7. **Market Dynamics**: The company is adapting to changes in the market, including price adjustments for generic drugs and the impact of new procurement policies on profitability [15][16]. 8. **Raw Material Pricing**: The company anticipates a stable recovery in raw material prices, with a focus on maintaining quality and managing costs effectively [17][18]. 9. **International Market Strategy**: The company is expanding its presence in international markets, particularly in Europe and the U.S., while managing domestic supply effectively [24][27]. 10. **Future Outlook**: The company expects a growth rate of over 30% in its external market segment, driven by new product launches and improved marketing strategies [20][22]. Additional Important Information - The company is focusing on building a robust pipeline of innovative drugs while maintaining a strong presence in the generic market [35]. - The management highlighted the importance of quality control and regulatory compliance in maintaining competitive advantages in both domestic and international markets [30][31]. - The company is also addressing the competitive landscape posed by Indian manufacturers, emphasizing the efficiency and quality of its production processes [27][28]. This summary encapsulates the key discussions and insights from the conference call, providing a comprehensive overview of the company's strategic direction and market positioning.

那么就是到去年年底呢我们在就是整个的运达这里合成了整个整个这个新能源电站的大概是4.6个G瓦那另外呢就是去年的话我们新增电网是是55万千瓦我们到年底呢就在手在手的电网容量呢是是102万千瓦就刚刚刚好差不多一个G瓦那么去年呢出售了两个电站总共出售了25万千瓦的电站 那二五年的话呢我们预计了我们自己定的目标大概希望今年能够能够能够自己变的变化呢是按照按照按照一个计划按照一个计划怎么去关转让呢这个还是要结合经营的情况包括电站的情况那么原则上的还是按照我们公司整体的就是说一些电站持有一些电站一些一些电站会做转让这个这个这个方式啊嗯另外一些呢就是关于一些就是其他板块啊 那其他很快呢就是关于这个综合服务这边那么我们其实现在除了海外销售销售主义之外呢我们最近在在越南的确实是接受了机遇的一些风机提供一些用为服务 我们感觉也还是交出了一个比较比较这个稳健的一个答卷那那为什么您这边就方便先就这个24年的这个年报的一些关键的一些经营经营业绩的一个情况啊包括企业呃日常这个经营管理当中的一些24年的一些工作的亮点能不能先给大家介绍一下谢谢啊好的那这样就结合年报的数据啊这个嗯简单介绍一下那么 这个本公司的情况呢一二四年一到十二月份的呢整 ...

大家好欢迎参加中泰交运日少港2024年报业绩交流目前所有参会者均处于静状态下面开始播报名字声明声明播报完毕后主持人可直接发言谢谢本次电话会议服务于中泰证券正式签约客户 未经中泰证券授权请勿对外传播本次会议的内容包括但不限于视频音频文字记录内容等信息感谢您的理解与配合中泰证券对违反上述要求的行为保留追究法律责任的权利市场有风险投资需谨慎本会议信息仅供参考不代表任何投资建议本公司不对任何人因使用本会议中的信息所引致的任何损失负担任何责任 好的各位线上的领导各位投资者大家好欢迎来到中泰证券线上会客室我是中泰证券交易人员杜冲那么今天这个时间段我们也是非常荣幸的邀请到日照港来做客中泰证券线上会客室跟大家一起交流2024年的财报和近期的经营情况 我们确实也是非常荣幸有这个机会啊邀请到公司多位领导来参加此次的这么一个线上的交流那么今天的交流的话呢也是分为两个部分那么首先呢第一部分的话呢是公司介绍那么第二个部分的话呢就是未来交流那么接下来的话呢我把时间呢交给公司交给董秘伟学勤伟总哎伟总听得见吗辛苦你哎听得见杜总 好的 杜总 各位投资者 大家上午好我是公司的董益伟学勤首先非常感谢中泰证券组织的本次电话会议也很感谢各位投资者一直 ...

分布式光谱的这个建设那么去年我们披露的这个20万的这个分布式光谱呢20万这个的分布式光谱呢在今年的将相继这个并往去发电那么同时呢我们会在拿 或者是领取一些这个中宇集团这个新的一些分布式光束建设这个项目那么去逐步壮大自己的规模同时的话呢这个按照目前的这个电价交易的这个原则或者我们去推动这个以大带小以大带小的这个风电的这个建设那么这是这个银行能源的这个基本情况 我们电量上升主要是因为气电率的提升还是说是因为一个风况的改善呀还是说是我们以大待小因为我们2023年以后我们的电量我们的电量上升是由于这个风况资源相比23年的好再加上这个24年的这个光资源也比23年的好导致这个整体就是发电量上升明白就是就是就是说我们以大待小的利用率 好的好的好的感谢杨总的介绍那我这边就先抛赃引益也先跟公司交流请教一下问题就是首先还是要回到我们2024年的主页的经营情况我们分季度来看分电源的就是或者整体电源的一个电量的定价情况是怎样一个情况呀杨总那这个 就是风机的一个利用小数这一块短期会有改善吗因为我们做一大袋小事就是想要做一件稍微做好做一件好的东西嘛简单的说来像贺兰山的一大袋小事按照23年的没有改造之前的利用率它应该是不到100个小时改造 ...

这个给大家介绍一下好了行那我们有请张博士嗯哎好的好的大家大家晚上好那个是这样的就是呃天籁机器人这个话题可能机器人是今年比较热门比较流行的话题是得益于春晚这几个表演榆树的表演之后大家对这个东西的关注度就非常高啊那个各个这个零配件材料厂商都在都在去关注这个事情包括咱们这个官方也在关注 谢谢各位领导各位投资人大家好我是东方采富的周旭辉今天我们非常荣幸的请到了天籁科技的董事长郑总董秘蔡总以及其他的技术高管和我们交流天籁科技是底电视材料细分领域的龙头最近也在积极的布局人行区线这个赛道我们的一个研究发现 电子皮肤以及其他的一些人形机器人的零部件需要用到碳纳米管而这个材料天爱科技是国内的绝对的龙头并且在这个领域已经有一些进展了那么下面把这个时间交给天爱科技的高管先我们有请郑总给我们介绍一下公司的情况 各位大家好我们今天的计划是让我们的张博士讲解一下给大家解释一下讨论一下我们在机器人当中的哪些点是跟我们的单笔管和多笔管相关的然后大家有什么疑问我们再来进一步讨论好吧我们交给我们公司的张博士 这个现在在手机里面已经有一些这个直接的一些应用啊然后还有一些抗击链模组啊气味传感器然后能源系统的主要是就是我们说的这个锂电池系统当然这个东 ...

設計為客戶提供從項目諮詢設計施工管理到系統調適運行管理保固維修等一系列專業化技術服務公司秉持多客戶多產業多工種多區域的發展策略行業卓越的服務品質高效的項目執行能力及專業的人才團隊營運範圍以布局全球多個國家地區 各位股东投资者朋友们大家好感谢您参与本次社会集成2024年度业绩说明会将从下面四方面对社会集成2024年度的经营情况向各位股东做简单的介绍 社会集成自2003年9月在苏州成立以来历经了20年的深耕以卓越的行业努力以前瞻性的布局构建了覆盖全球的服务体系成为行业领先的半导体服务供应商境内业务以苏州总部为战略中心 建立华东、华中、华南三大经济带的服务体系通过合肥、郑州、长沙、武汉、重庆等区域城市战略性布点,形成对先进制造业的精准更改依照各区域的优势 打造总部加区域的双核模式构建快速响应机制及贴身服务体系实现与下游高端服务客户的技术需求无缝对接 中南亚地区已成为公司海外事业版图开拓的核心区域公司旗下的马来西亚、印度尼西亚、泰国、越南等公司以国内为坚实后盾实现原物料、技术及人力的高端互补与协同供应公司业务在中南亚各国单点突破逐步拓展为一张紧密相连的网络 各地质公司相辅相成,协同共进业务发展空间愈发灵活且具有弹性质 ...

Summary of Conference Call for Chunli Medical Company Overview - Chunli Medical is a leading orthopedic medical device company in China, focusing on the research, production, and sales of implantable orthopedic medical devices, including products for joints, spine, sports medicine, and trauma [2][4]. Key Points and Arguments Business Development and Market Position - The company has successfully expanded its product line and increased its market share, particularly in the orthopedic high-value medical consumables sector [2][3]. - Chunli Medical has actively participated in national centralized procurement policies, successfully winning bids for multiple product categories, including joint and spine products [3][16]. - The company reported a significant increase in overseas sales, which grew by 78.31% year-on-year, accounting for 43.88% of total revenue [5][17]. Financial Performance - For 2024, Chunli Medical reported total revenue of 806 million yuan, a decrease of 33.32% compared to the previous year [16][17]. - The net profit attributable to shareholders was 125 million yuan, with a basic earnings per share of 0.33 yuan [16][17]. - The gross margin for 2024 was 66.65%, down by 5.85 percentage points, primarily due to price reductions from centralized procurement [17]. Research and Development - The company has committed to increasing its R&D investment, with 133 million yuan allocated for 2024, representing 16.52% of total revenue [6][17]. - Chunli Medical has a strong R&D team, with 347 technical personnel, including many with advanced degrees and extensive industry experience [6]. Product Innovation and Regulatory Approvals - Chunli Medical has achieved several significant regulatory approvals, including CE certification and FDA 510K for various products, enhancing its international market competitiveness [7][9]. - The company has developed innovative products, including 3D-printed orthopedic implants and biodegradable medical materials, filling gaps in the domestic market [11][12]. Cash Dividend Policy - The company proposed a cash dividend of 0.49 yuan per share, totaling approximately 18.75 million yuan, which represents 40.42% of the net profit attributable to ordinary shareholders [18][19]. Other Important Information - Chunli Medical is recognized as a national high-tech enterprise and has received multiple accolades for its innovation and contributions to the industry [5][10]. - The company is actively pursuing mergers and acquisitions to enhance its product offerings and market presence [15]. This summary encapsulates the key aspects of Chunli Medical's conference call, highlighting its business strategies, financial performance, R&D efforts, product innovations, and shareholder returns.

Summary of Conference Call Company and Industry - The conference call primarily discusses the jewelry industry, specifically focusing on a company involved in gold and jewelry sales, as well as its product offerings and market strategies. Key Points and Arguments 1. **Sales Performance and Market Trends** - The company anticipates a year-on-year improvement in sales for the first quarter, although the growth may not be significant due to high gold prices affecting consumer behavior [1][2] - The worst sales performance was noted in the second quarter of the previous year, with expectations of gradual recovery in subsequent quarters [2] 2. **Product Development and Branding** - The company is leveraging the concept of "National Treasures" to enhance product offerings and store branding, which has led to improved sales and market presence in high-end shopping centers [3][4] - There is a focus on creating a product line that incorporates well-known cultural artifacts, which has shown to significantly increase product pricing and consumer interest [3] 3. **Store Expansion and Market Penetration** - The company has opened over 100 new stores in the past year, with expectations to exceed this number by year-end [7] - The introduction of themed stores based on the "National Treasures" concept has allowed the company to enter previously inaccessible high-end retail channels [4] 4. **New Product Lines** - A new brand called "Zhu Chuang" has been launched, focusing on a niche market within the jewelry sector, which has shown promising initial sales performance [10] - The company is exploring various materials and product types to cater to emerging consumer demands, particularly in smaller, high-margin product categories [11][12] 5. **Sales Strategy and Pricing** - The company is adjusting its pricing strategy, with a notable shift towards fixed-price offerings, which currently account for approximately 10-20% of total sales volume [14] - The overall sales strategy is aimed at maintaining a stable dividend policy, reflecting a strong cash flow position without significant capital expenditures [15] 6. **E-commerce and Market Expansion** - Plans for expanding e-commerce operations are underway, with a focus on international markets, particularly through platforms like Amazon [16] - The company is also considering adjustments to its supply chain and service offerings to enhance overall market competitiveness [18] Other Important Content - The discussion highlighted the impact of high gold prices on consumer behavior, with some consumers looking to liquidate assets while others are entering the market [8] - The company is in the preparatory stages for potential new branding initiatives, which may include collaborations with state-owned entities, although these plans are still uncertain [5][6] - The conference concluded with an invitation for investors to engage further regarding the jewelry industry and the company's future prospects [19]